Stay updated on Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Sign up to get notified when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.

Latest updates to the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page shows a revision update from v3.6.4 to v3.6.5, representing a version bump. There are no visible changes to the study details or content.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedThe site’s revision tag changed from v3.6.3 to v3.6.4 to reflect an update.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page shows a new revision tag (v3.6.3), signaling a backend update; this change does not appear to affect the study details displayed.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page now displays a newer site revision label (v3.6.2) replacing the previous v3.6.0, indicating a software release for the page. This update does not alter the study details, eligibility criteria, or results displayed on the page.SummaryDifference0.1%

- Check73 days agoChange DetectedThe study page now shows that no participants are being sought, updating the recruitment status to completed. Additionally, new help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study), and a small formatting change updated the Intervention/Treatment label while the site revision progressed from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check80 days agoChange DetectedThe page now displays Revision: v3.5.5, replacing the previous Revision: v3.5.4, indicating an update to the page's versioning.SummaryDifference0.1%

Stay in the know with updates to Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.